As of 2025-07-08, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -1.47. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 529.00 mil USD. SAGE's TTM EBITDA according to its financial statements is -358.92 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 12.6x | 12.5x |
| Forward P/E multiples | 20.4x - 43.4x | 31.9x |
| Fair Price | (116.20) - (71.50) | (126.52) |
| Upside | -1367.2% - -879.7% | -1479.7% |
| Date | EV/EBITDA |
| 2025-07-03 | -1.48 |
| 2025-07-02 | -1.46 |
| 2025-07-01 | -1.46 |
| 2025-06-30 | -1.47 |
| 2025-06-27 | -1.47 |
| 2025-06-26 | -1.49 |
| 2025-06-25 | -1.49 |
| 2025-06-24 | -1.48 |
| 2025-06-23 | -1.50 |
| 2025-06-20 | -1.50 |
| 2025-06-18 | -1.47 |
| 2025-06-17 | -1.47 |
| 2025-06-16 | -1.46 |
| 2025-06-13 | -1.04 |
| 2025-06-12 | -1.03 |
| 2025-06-11 | -1.06 |
| 2025-06-10 | -1.09 |
| 2025-06-09 | -1.06 |
| 2025-06-06 | -1.07 |
| 2025-06-05 | -1.06 |
| 2025-06-04 | -1.02 |
| 2025-06-03 | -1.01 |
| 2025-06-02 | -1.03 |
| 2025-05-30 | -1.00 |
| 2025-05-29 | -1.01 |
| 2025-05-28 | -1.00 |
| 2025-05-27 | -1.01 |
| 2025-05-23 | -1.01 |
| 2025-05-22 | -1.03 |
| 2025-05-21 | -1.06 |
| 2025-05-20 | -1.12 |
| 2025-05-19 | -1.11 |
| 2025-05-16 | -1.08 |
| 2025-05-15 | -1.03 |
| 2025-05-14 | -0.99 |
| 2025-05-13 | -1.03 |
| 2025-05-12 | -1.05 |
| 2025-05-09 | -1.02 |
| 2025-05-08 | -1.04 |
| 2025-05-07 | -1.06 |
| 2025-05-06 | -1.07 |
| 2025-05-05 | -1.12 |
| 2025-05-02 | -1.15 |
| 2025-05-01 | -1.18 |
| 2025-04-30 | -1.15 |
| 2025-04-29 | -1.20 |
| 2025-04-28 | -1.23 |
| 2025-04-25 | -1.23 |
| 2025-04-24 | -1.23 |
| 2025-04-23 | -1.20 |